Clinical Trials Logo

Epilepsy clinical trials

View clinical trials related to Epilepsy.

Filter by:

NCT ID: NCT06466681 Recruiting - Clinical trials for Temporal Lobe Epilepsy

Changes in Attentional Control After a Focal Seizure.

ATTENTIONEPIF
Start date: March 4, 2024
Phase:
Study type: Observational

Epilepsy is frequently associated with cognitive and attentional disorders. Several studies have pointed out that there are modifications of brain activity in resting state during peri-ictal period in EEG and functional MRI. However, to date, no study has assessed the changes in attentional control after a seizure. The investigators hypothesize that a localized discharge is associated with a disorganization of the networks engaged in attentional control. In this regard, the investigators propose a prospective longitudinal study assessing the changes in attentional control after a focal seizure.

NCT ID: NCT06462911 Not yet recruiting - Epilepsy Clinical Trials

Epilepsy Self-Management for Spanish Speakers: HOBSCOTCH - ESPANOL

Start date: June 2024
Phase: N/A
Study type: Interventional

The goal of this pilot study is to assess the feasibility of translating and delivering the existing home-based epilepsy self-management intervention, HOBSCOTCH, for people with epilepsy whose primary language is Spanish. The main questions it aims to answer are: 1. Can the current HOBSCOTCH program be successfully translated for Spanish speaking people with epilepsy? 2. Will people with epilepsy who speak Spanish experience improved quality of life similar to that found in people with epilepsy who received the HOBSCOTCH program in English? Participants will be asked to: - attend nine, one-hour virtual (online and/or by telephone) HOBSCOTCH-SPANISH sessions with a one-on-one certified bilingual HOBSCOTCH coach - complete a brief clinical questionnaire about their diagnosis of epilepsy - complete two questionnaires before and after the HOBSCOTCH sessions about their quality of life and about memory and thinking processes - keep a short daily diary about their seizures, symptoms and use of the self-management strategies taught in the HOBSCOTCH program - complete a brief Satisfaction Survey and a 3 question survey about shared decision making after the entire HOBSCOTCH program

NCT ID: NCT06453213 Not yet recruiting - Focal Onset Seizure Clinical Trials

Open-label Study of Cenobamate Monotherapy in Adult Subjects With Newly Diagnosed or Recurrent Partial-Onset Epilepsy

Start date: July 18, 2024
Phase: Phase 4
Study type: Interventional

Cenobamate (YKP3089) is a small molecule approved in the United States (US), Europe and several other countries around the world for the treatment of Partial-Onset (focal) seizures in adult subjects (≥18 years of age). In the US it is approved for use as monotherapy, however, there is little clinical data assessing its use as monotherapy in adults with POS. This study is designed to explore the effectiveness of doses of 100 mg/day and 200 mg/day as monotherapy in adult subjects with newly diagnosed or recurrent POS/focal onset epilepsy.

NCT ID: NCT06450236 Completed - Epilepsy Clinical Trials

Bioequivalence Study of Perampanel Tablets 10 mg

Start date: November 22, 2023
Phase: Phase 1
Study type: Interventional

An open-label, balanced, randomized, two treatment, two sequence, two period, two way cross-over, single dose bioequivalence study of Perampanel Tablets 10 mg of Humanis Sağlık A.ġ., Turkey and Fycompa 10 mg film-coated tablets of Eisai GmbH Edmund-Rumpler-Straße 3 60549 Frankfurt am Main Deutschland in normal, healthy, adult, human subjects under fasting condition.

NCT ID: NCT06450223 Completed - Epilepsy Clinical Trials

Bioequivalence Study of Perampanel Tablets 12 mg

Start date: September 14, 2023
Phase: Phase 1
Study type: Interventional

An open-label, balanced, randomized, two treatment, two sequence, two period, two way cross-over, single dose bioequivalence study of Perampanel Tablets 12 mg of Humanis Sağlık A.ġ., Turkey and Fycompa 12 mg film-coated tablets of Eisai GmbH Edmund-Rumpler-Straße 3 60549 Frankfurt am Main Germany in normal, healthy, adult, human subjects under fasting condition.

NCT ID: NCT06444126 Recruiting - Clinical trials for Epilepsy in Children

The Incidence And Risk Factors Of Recurrent Febrile Seizures And Epilepsy Following Febrile Seizures

Start date: March 15, 2023
Phase:
Study type: Observational

The goal of this observational study is to learn about the recurrence and development of epilepsy in children hospitalized with their first febrile seizures. The main questions it aims to answer are: - What is the risk of recurrence after the first febrile seizure and what are the risk factors for recurrent febrile seizures in Vietnamese children? - What is the risk of developing epilepsy later in life and what are the risk factors for developing epilepsy in Vietnamese children who have had febrile seizures?

NCT ID: NCT06443463 Not yet recruiting - Focal Epilepsy Clinical Trials

Long-term Safety and Tolerability of BHV-7000

Start date: July 2024
Phase: Phase 2
Study type: Interventional

A study to determine if BHV- 7000 is safe and tolerable in adults with refractory focal onset epilepsy

NCT ID: NCT06436547 Not yet recruiting - Clinical trials for Epilepsy, Drug Resistant

Subiculum Electrical Stimulation for Temporal Lobe Epilepsy With Biliteral Hippocampus Sclerosis(SESTB)

Start date: May 30, 2024
Phase: N/A
Study type: Interventional

The primary objective of this research is to study the efficacy and safety of deep brain stimulation (DBS) of Subiculum as adjunctive therapy for reducing the frequency of seizures in drug-resistant temporal lobe epilepsy with bilateral hippocampal sclerosis

NCT ID: NCT06432231 Completed - Quality of Life Clinical Trials

Effects of Low Glycemic Index Diet in Children With Drug-resistant Epilepsy

Start date: August 28, 2022
Phase: N/A
Study type: Interventional

The goal of this clinical trial was to evaluate the effectiveness of a low glycemic index diet (LGID) on seizure frequency, oxidative stress markers and quality of life in children with drug-resistant epilepsy. Based upon the aims, the following hypotheses were tested: 1. LGID reduces seizure frequency in children with drug-resistant epilepsy. 2. LGID improves oxidative parameters in children with drug-resistant epilepsy 3. LGID improves quality of life and mental health in children with drug-resistant epilepsy Participants were prescribed the LGID for 3 months.At baseline and at outpatient clinic follow-ups at 3 months, anthropometric measurements were taken, the strengths and difficulties questionnaire (SDQ), Pediatric Inventory of Quality of Life (PedsQL) and depression scales were administered and samples for biochemical measurements were collected. Diet compliance was evaluated by food consumption records during monthly follow-up visits (at 1 , 2, and 3 months).

NCT ID: NCT06427967 Not yet recruiting - Epilepsy Clinical Trials

A Novel Social Emotional Learning Curriculum for Youth With Epilepsy

Start date: June 2024
Phase: N/A
Study type: Interventional

Youth with epilepsy (YWE) are significantly more likely than their peers without epilepsy to experience isolation, interpersonal victimization, and low relationship satisfaction. This is a serious health concern. Poor social support, real or perceived, is consistently correlated to worsened outcomes in every domain of health-related quality of life. As YWE are two to five times more likely than their peers without epilepsy to develop a mental health condition, poor social support is likely a bidirectional risk factor. Currently, there are no best practices or recommendations for clinicians or other youth-serving professionals to reference when it comes to improving the perceived social support of YWE specifically. The research team has drawn from multiple fields of scientific knowledge to develop a novel intervention that aims to provide YWE with knowledge, skills, connections, and positive emotional support that can help them to bolster their support system at every level of the social ecological model (SEM). The proposed study is a pilot of this intervention to test its acceptability and appropriateness according to YWE participants ages 12 to 26. The intervention's impact on participants social-emotional learning skills and the feasibility of expanding the study protocol for use in a large, multisite randomized control trial will also be explored. The goal of this research study is to help evaluate a new program for young people diagnosed with epilepsy that will build up young people's social opportunities, interpersonal skills, and sources of emotional support. The investigators want to research the impact of this program. From this study, the investigators hope to learn what the program does well, and in what ways it could be improved from the perspective of YWE.